{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:16:42Z","timestamp":1783487802638,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116881","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:44:58Z","timestamp":1781333098000},"page":"116881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer"],"prefix":"10.1016","volume":"243","author":[{"given":"Danny","family":"Lavigne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Le P\u00e9choux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Botticella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jouveshomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Guezour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Naltet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2026.116881_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.116881_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ejca.2026.116881_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2026.116881_bib7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2026.116881_bib9","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.ejca.2026.116881_bib10","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116881_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtho.2025.05.012","article-title":"Amivantamab in participants with advanced NSCLC and MET Exon 14 skipping mutations: final results from the CHRYSALIS study","volume":"20","author":"Krebs","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canrad.2023.03.002","article-title":"Radiotherapy in the management of synchronous metastatic lung cancer","volume":"28","author":"Khalifa","year":"2024","journal-title":"Cancer\/Radio\u00e9rapie"},{"issue":"12","key":"10.1016\/j.ejca.2026.116881_bib13","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non\u2013small cell lung cancer\u2014a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116881_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102621","article-title":"Local control strategies for management of NSCLC with oligoprogressive disease","volume":"120","author":"Mavrikios","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ejca.2026.116881_bib15","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116881_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116881_bib17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1200\/OP.24.00216","article-title":"Antineoplastic therapy administration safety standards for adult and pediatric oncology: ASCO-ONS standards","volume":"20","author":"Siegel","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.ejca.2026.116881_bib18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ejca.2026.116881_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejca.2026.116881_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ijrobp.2016.08.033","article-title":"The effect of biologically effective dose and radiation treatment schedule on overall survival in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy","volume":"96","author":"Stahl","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejca.2026.116881_bib21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ijrobp.2024.07.2336","article-title":"Is local ablative stereotactic radiation therapy a valuable rescue strategy for time on drug in patients enrolled in phase I trials?","volume":"120","author":"Mavrikios","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"10185","key":"10.1016\/j.ejca.2026.116881_bib22","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"10422","key":"10.1016\/j.ejca.2026.116881_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116881_bib24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtho.2023.11.020","article-title":"Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116881_bib25","article-title":"Pneumonitis in patients receiving thoracic radiotherapy and osimertinib: a multi-institutional study","volume":"4","author":"Banla","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2026.116881_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103435","article-title":"Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"87","author":"Sampath","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejca.2026.116881_bib27","doi-asserted-by":"crossref","first-page":"S1614","DOI":"10.1016\/j.annonc.2025.09.086","article-title":"LBA72 NorthStar: a phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)","volume":"36","author":"Elamin","year":"2025","journal-title":"Ann Oncol"},{"issue":"10515","key":"10.1016\/j.ejca.2026.116881_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2026.116881_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"10481","key":"10.1016\/j.ejca.2026.116881_bib30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2026.116881_bib31","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S1470-2045(24)00664-8","article-title":"Innovative, early-phase clinical trials of drug-radiotherapy combinations","volume":"26","author":"Levy","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116881_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jtho.2024.04.006","article-title":"Treatment response biomarkers: working toward personalized radiotherapy for lung cancer","volume":"19","author":"Horne","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"9, Supplement","key":"10.1016\/j.ejca.2026.116881_bib33","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.jtho.2022.07.861","article-title":"EP08.03-005 HALT - targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours","volume":"17","author":"McDonald","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116881_bib34","first-page":"115","article-title":"Stereotactic ablative radiotherapy for oligo-progressive disease refractory to systemic therapy in non-small cell lung cancer: a registry-based phase II randomized trial (SUPPRESS-NSCLC)","volume":"33","author":"Bahig","year":"2022","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:47:12Z","timestamp":1783486032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"alternative-id":["S0959804926006623"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116881","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116881"}}